Innovative therapeutic agents have significantly improved outcomes, with an acceptable safety profile, in a substantial proportion of non-small cell lung cancer (NSCLC) patients in whom the malignant phenotype of the disease is determined by oncogenic molecular alterations. However, the benefit seen with these treatment models has not translated well 
INTRODUCTION
Over the past 10 years, the discovery of molecular alterations susceptible to targeted inhibition has significantly improved overall survival (OS) in a small group of non-small cell lung cancer (NSCLC) patients [1] [2] [3] [4] [5] . However, subgroups of oncogenic drivers that are targetable are not common [6] , and overall treatment outcomes of NSCLC patients remain unsatisfactory, with low long-term survival rates.
Direct inhibition of Kirsten Rat Sarcoma
Viral oncogene homolog (KRAS), the most commonly mutated oncogene in lung adenocarcinoma, has proven clinically challenging [7] . The KRAS gene is located in the short arm of chromosome 12 and encodes for two splice variants, KRAS4A and KRAS4B [8] . Mutated KRAS has a putative role in NSCLC, most frequently observed in tumors arising in smokers with adenocarcinoma histology [9, 10] .
RAS mediates the intracellular signaling pathway in response to activation of cell surface receptors. Once activated, a tyrosine kinase receptor binds to an adaptor protein, Grb2, which recruits the guanine nucleotide exchange factor SOS. SOS facilitates the RAS GDP-GTP exchange, leading to RAS activation, which in turns stimulates the RAF-MEK-ERK mitogen-activated protein kinase (MAPK), the phosphatidylinositol 3-kinase (PI3K)-AKTmTOR and the RAS-like (RAL) pathways (Fig. 1 ). RAS signaling is switched off by
GTPase activating proteins (GAPs) responsible for GTP hydrolysis [11] . KRAS mutations, which impair GTP hydrolysis, are located in the sites involved in GAP binding, including codons 12, 13 and 61, with the amino acid substitution G12C being the most common [7, 9- non-preplanned analysis, performed to build an immunohistochemistry score for EGFR expression, confirmed that high EGFR levels are more commonly detected in LSCC than in other types of NSCLC [22] . It was not possible to fully validate these results in a second phase III trial (BMS099), in which cetuximab showed no benefit in OS, progression-free survival (PFS) or response in combination with first line carboplatin and docetaxel [23] .
In the SQUIRE trial, necitumumab plus cisplatin and gemcitabine was compared to cisplatin and gemcitabine alone for advanced LSCC. The study met its primary endpoint, 
REVISITING STAT3 SIGNALING IN KRAS MUTANT NSCLC AND LSCC
Deregulation of signal transducer and activator of transcription (STAT3) has been observed in different tumors [26] . Phosphorylation at tyrosine (Tyr) 705, in response to growth factors and cytokines, is required to activate STAT3. Upon Janus kinase (JAK) activation, growth factor receptors or cytokine receptors create docking sites to recruit cytoplasmic STAT3 which dimerizes, translocates into the nucleus and promotes the transcription of genes involved in cell cycle progression and apoptosis ( Fig. 1 ) [27] .
Preclinical data showed that phosphorylated STAT3 increases following MEK inhibition in KRAS mutant cells [28] . STAT3 contributes to drug resistance through activation of FGFR and JAK. Combinatorial treatment with the dual JAK1 and FGFR inhibitor ponatinib and the MEK inhibitor selumetinib suppressed STAT3 phosphorylation in vitro [28] . Similar results were observed in vivo, in which concomitant treatment with either ponatinib and GDC0973 (MEK inhibitor), or ruxolitinib (JAK1/2 inhibitor) with GDC0973, or the triple combination of ruxolitinib, ponatinib and GDC0973, significantly reduced tumor growth [28] . By exploring the pathogenic contribution of STAT3 in KRAS mutant tumors, Brooks et al. found that augmented levels of only interleukin 6 (IL-6) and its essential trans-signaling receptor subunit, sIL-6R, are observed in lung adenocarcinoma patients, and are also associated with exacerbated KRAS G12D-driven lung carcinogenesis in mice [29] .
Another emerging key role of STAT3 is related to its mitochondrial activation upon 
PAK PROTEIN KINASES AND THEIR ROLE IN CANCER
The p21-activated kinase (PAK) family includes six serine/threonine protein kinases, classified into two groups, PAK1-3 (group I) and PAK 4-6 (group II), with PAK1 being the most extensively studied [45] . PAK1 may be deregulated in tumors through gene amplification of the locus 11q13, messenger RNA overexpression or activating mutations [46] phosphorylation at Ser298 [50] . PAK1 also acts as a scaffold protein that recruits AKT to the plasma membrane allowing its activation ( Fig. 1 ) [51] . In a transgenic mouse model of squamous skin carcinoma harboring KRAS G12D, the lack of PAK1 significantly delayed and reduced tumor development [52] . Biochemical analyses revealed a strong reduction of MEK-ERK and AKT activation in PAK1-negative tumors. However, the available data suggest that ERK has a more determining role in tumorigenesis than AKT, as observed after treatment with ERK and AKT inhibitors. In the same model, RAC1 was found to be a critical player, since the lack of RAC1 is associated with a decreased keratinocyte hyperproliferation and with MEK and AKT activation [53] . PAK1 also phosphorylates CRAF at Ser338. Phosphorylated CRAF translocates into mitochondria and phosphorylates BAD, which prevents the binding to B cell lymphoma-2 (BCL-2), and inhibits apoptosis (Fig. 1 ) [54] . [55] . Nuclear localization of PAK1 was evident in a significant proportion of LSCC while lung adenocarcinomas and SCLCs expressed weak to moderate levels of PAK1 only in the cytoplasm [55] . Interestingly, epidermal growth factor has been found to stimulate PAK1 activity in HNSCC (Fig. 1 ) [56] . When PAK1 mRNA expression was examined in a distinct set of 54 laser-capture microdissected lung tissues, PAK1 mRNA expression was highest in LSCC compared with normal lung [55] . PAK1 inhibition in LSCC cell lines determines accumulation in the G1 phase.
Levels of the E2F1 transcription factor, which regulates gene expression associated with DNA replication and mitosis and is essential for G1/S progression, were diminished after PAK1
ablation [55] . In LSCC xenograft models, PAK1
inhibition impaired tumor growth, as confirmed by a reduction of Ki-67 expression [55] . PAK1 inhibition alone did not increase apoptosis in NSCLC cells and xenograft models but displayed dramatically enhanced efficacy when combined with apoptosis proteins, EGFR, MEK1/2, or Src inhibitors [55] .
Additional studies are warranted to better explore the role of PAK proteins in cancer.
Several PAK inhibitors have been synthesized but are still in early stages of clinical development [57] . For instance, PF3758309 was investigated in a phase I study, but development was not continued due to unfavorable pharmacokinetic properties.
FRAX-597 is a group I PAK inhibitor, able to prevent ATP binding, with in vivo antitumor activity in a KRAS model [58] . Interestingly, the racemic form of the anti-inflammatory ketorolac, R-ketorolac, beyond cyclooxygenase (COX1/2) inhibition, suppresses RAC1 and Cdc42 [59, 60] . Ivermectin, a well-tolerated antiparasitic macrocyclic lactone has also been found to block PAK1 in human ovarian cancer [61] (Table 1) .
THE HIPPO PATHWAY AS A NEW TARGET FOR LUNG CANCER TREATMENT
The Hippo pathway is a complex signaling system, initially identified in Drosophila and responsible for organ size regulation [62] . and YAP1 (Fig. 1) . NF2 inhibits RAC1, thus preventing PAK1-mediated phosphorylation of CRAF and MEK [74] . At the same time, NF2
phosphorylates YAP1, thereby blocking its nuclear translocation, and reduces transcription of the RAS genes with a TEAD binding site in their promoter [74] . Lack of NF2, due to loss of chromosome 22q, is detected in 45% of RAS mutant PTCs and is associated with marked sensitivity to selumetinib [74] .
YAP1 overexpression is correlated with lymph node metastasis, pTNM stage and poor prognosis of both lung adenocarcinoma and LSCC [75] . YAP1 has been recognized as a marker of resistance to cetuximab in colorectal cancer patients [76] . YAP1 activation leads to overexpression of EGFR and its ligand amphiregulin (AREG) (Fig. 1) [77, 78] . It has also been demonstrated that extracellular matrix deprivation activates the Hippo pathway and inactivates YAP1 in lung adenocarcinoma, which eventually initiates the squamous trans-differentiation programme [79] .
The YAP1-TAZ pathway may be suppressed by compounds that target the upstream Src kinase or by small molecules that prevent YAP-TEAD interaction (Table 1) . Src inhibitors like saracatinib, dasatinib or bosutinib have been clinically investigated [80] . In vitro data indicate activity not only against Src kinase but also EGFR even though there are few differences in terms of mechanism of action. Saracatinib is the most efficient at inhibiting mutant EGFR, thanks to a mechanism of action independent from Src which is not yet fully understood [81, 82] . Dasatinib exhibits the highest inhibition potential for Src Kinase and wild-type EGFR [83] , suggesting that combination with selumetinib or necitumumab could be a very promising treatment strategy for patients with KRAS mutated NSCLC and LSCC, respectively.
Small molecules interfering with YAP-TEAD interaction hinder YAP1-induced gene transcription and are also efficient in NF2 inactivation. Verteporfin, currently used in combination with photodynamic therapy to treat macular eye degeneration, was the first investigated YAP1 inhibitor [84] . Super-TDU blocks YAP1-TEAD complexes, mimicking the action of vestigial-like family member 4 (VGLL4), the tumor suppressor that competes with YAP1 for TEAD binding (Fig. 1) [85] . Finally, ivermectin, besides its activity against PAK1 [61] , has been identified as a potential YAP1 inhibitor through a mechanism that is not yet clear [86] (Table 1) .
AXL: BIOLOGICAL FUNCTIONS AND THERAPEUTIC IMPLICATIONS
AXL (from the Greek word 'anexelekto,' or uncontrolled), a direct transcriptional target of YAP1, is a tyrosine kinase receptor involved in the epithelial mesenchymal transition (EMT) process [87] . It is a potent oncogene that modulates resistance to conventional and targeted cancer therapies [88] . A gene found, suggesting that heterodimeric complexes involving the ERBB signaling can emerge following MEK inhibition [90] . We were able to identify AXL as the most overexpressed gene in tumors with acquired resistance to erlotinib [88] . In our in vitro and in vivo models, AXL overexpression was related to NF-jB activation while knockdown of AXL restored sensitivity to erlotinib treatment in in vivo models [88] . We additionally identified AXL overexpression as a mechanism of acquired resistance to cetuximab in NSCLC and HNSCC [91] . In fact, EGFR directly regulates expression of AXL mRNA through MAPK signaling and the transcription factor c-Jun in cetuximab-resistant cells, creating a positive feedback loop that maintains EGFR activation by AXL (Fig. 1) [91] .
In addition, AXL blockade inhibits proliferation, migration and invasion in prostate cancer cell lines and in in vivo models through inhibition of the NF-jB pathway [92] . Intriguingly, AXL blockade inhibits the secretion of IL-6, which in turn reduces proliferation of androgen-insensitive prostate cancer cells via STAT3 inhibition [92] .
Several AXL inhibitors are currently under development. Most are ATP competitive kinase inhibitors, with cross-reactivity against multiple tyrosine kinase receptors ( Table 1 ). The lack of AXL kinase domain crystallographic models may explain the difficulties encountered during the development of AXL inhibitors [93] . Foretinib is a dual MET/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor, with activity against AXL [93] .
Cabozantinib, already approved for the treatment of medullary thyroid cancer, inhibits MET, VEGFR2, rearranged during transfection (RET), and AXL [93] . MGCD265 is a MET/VEGFR2 inhibitor also able to suppress AXL activity [93] . BMS-777607 was initially developed as a MET inhibitor but is more potent against AXL. Finally, BGB324/R428, specifically designed to target AXL, is the only compound with two phase I studies ongoing [93] .
UNRAVELING THE THERAPEUTIC POTENTIAL OF THE HEDGEHOG PATHWAY IN LUNG CANCER
The hedgehog (Hh) signaling pathway is highly conserved and has a crucial role in embryogenesis, adult tissue homeostasis and carcinogenesis [94] . Hh signaling is activated following binding of Sonic Hh (Shh), Desert Hh and Indian Hh ligands to their transmembrane receptor Patched (PTCH), leading to the release of Gli transcription factors by depressing Smoothened (SMO) (Fig. 1) [95] .
Ligand-dependent activation of the Hh pathway has been described in epithelial tumors, but SMO inhibitors have so far failed to show any benefit in clinical trials of pancreatic, colon or ovarian cancer [96, 97] .
Complex crosstalk between Hh and other pathways seems to play a significant role in resistance to Hh pathway inhibitors. LSCC tumors overexpress PKCiota, SOX2 and Hh acyltransferase (HHAT) and require
PKCiota-SOX2-HHAT signaling to maintain a stem cell phenotype ( Fig. 1 ) [98] . NSCLC cells overexpressing Gli1 can overcome the growth-inhibitory effects of Hh antagonist such as cyclopamine [99] through crosstalk between the Hh and EGFR signaling pathways. In fact, cooperation between Hedgehog and Gli-EGFR synergistically induces expression of SOX2 [100] . Targeting Hh signaling at the level of Gli may be more effective than targeting either Shh or SMO in LSCC. Gli2 is likely to be the major signaling transducer in LSCC and is the primary activator of Hh signaling, with Gli1 being a transcriptional target of Gli2 [101] . SMO has a minimal role in regulating LSCC survival via the canonical Hh pathway [101] . Loss of SMO did not reduce Gli2 mRNA level in LSCC cell lines and only Gli2 knockdown inhibited cell proliferation and survival and induced apoptosis [101] . The Hh pathway also seems to be involved in KRAS oncogene transformation [102] . Loss of Gli1 inhibits KRAS-induced pancreatic paraneoplastic lesions in mice. Shh promotes binding between Gli1 and the IL-6
promoter, thus favoring activation of STAT3 and gene transcription (Fig. 1 ) [102] .
Vismodegib is a first-in-class small-molecule SMO inhibitor approved for treatment of advanced basal skin carcinoma [103] . GANT61
is a Gli1 and Gli2 inhibitor [97] . The isoflavone genistein also inhibits Gli1 mRNA expression and downregulates Gli reporter activity [104] .
Among the catechins contained in green tea, epigallocatechin 3-gallate (EGCG) has been reported to inhibit prostate cancer and chondrosarcoma proliferation through Gli1 inhibition [105] . Finally, mebendazole, a drug approved for treatment of nematode infections, has been found to suppress the formation of the primary cilium, a microtubule-based organelle that functions as a signaling hub for Hh pathway activation [106] . 
CONCLUSION: FUTURE PERSPECTIVES

